New Initiative to Increase Global Access to HPV Vaccine
January 27th, 2023 | press-release
The human papillomavirus (HPV) vaccine is one of the most effective ways to prevent cervical cancer and other HPV-related diseases, yet there is still disproportionate access to it, specifically among girls and adolescents in low- and middle-income countries.
The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium was recently launched to increase and sustain equity, program quality, and accelerate coverage of HPV vaccination.
The consortium, funded by the Bill & Melinda Gates Foundation, strives to contribute to the Gavi, the Vaccine Alliance, goal of vaccinating 86 million girls and adolescents by 2025, and support the global goal of 90% HPV vaccination coverage by 2030.
JSI and HAPPI Consortium partners the Clinton Health Access Initiative, the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH will focus on enabling evidence-based policy decisions; enhancing and sustaining equity; improving program quality; providing direct technical assistance in selected countries; and monitoring, evaluating, and learning to build on the evidence base.
